Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia
Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia: a Multicenter, Single-blinded, Randomized Controlled Trial
Air Force Military Medical University, China
88 participants
Nov 1, 2024
INTERVENTIONAL
Conditions
Summary
Functional dyspepsia (FD) is a common gastrointestinal disease, which is associated with decreased life quality and increased medical cost. Antipsychotic drugs were demonstrated to be effective in relieving symptoms in FD patients, especially for patients with refractory FD. However, the use of those drugs was associated with obvious adverse events. Cognitive behavioral therapy (CBT) has extensive applications and exhibited potential treatment effects in clinical practices, especially for treating anxiety, depression, pain or stress disorders. Several previous RCT studies have confirmed the effects of psychological intervention on improving dyspepsia in FD patients. Our hypothesis was that 8-week smartphone-based CBT would be non-inferior to conventional pharmacotherapy in reducing FD-related symptoms in patients with refactory FD.
Eligibility
Inclusion Criteria3
- Age 18-80
- Refractory functional dyspepsia (patients with Rome IV functional dyspepsia remained symptomatic after treatment of 8 weeks of proton pump inhibitor and 4 weeks of prokinetics)
- Negative or unrelated-to-FD symptom findings of gastroscopy, upper abdominal ultrasound, Hp test and routine blood tests within the past 1 year.
Exclusion Criteria9
- Severe mental illness (PHQ-9 ≥20 or GAD-7 ≥15) or suicidal ideation;
- Known hp infection, active gastrointestinal peptic ulcer, cholecystitis, gallstones, suspected or known bowel obstruction, gastroparesis, major gastrointestinal surgery etc.;
- Known or suspected malignant tumor, significant heart/brain/liver/kidney diseases, obvious hematologic abnormalities or endocrine diseases etc., which may be -related to FD symptoms;
- Known or suspected drug-related FD (e.g.NSAIDs-related FD);
- Unable to access to mobile networks or unable to manage mobile APP properly.
- Allergy or other contradictions to flupenthixol or melitracen
- Taking any antipsychotics drugs or CBT interference within 12 weeks
- Pregnant or lactating women;
- Unable to provide informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The CBT mobile application enables patients to conduct cognitive therapy independently.
patients take Flupentixol and Melitracen Tablets
Locations(7)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06756139